Follow The Filings

SPRY ARS Pharmaceuticals

ARS Pharmaceuticals earnings company data as of 4:47 AM ET 10/22

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — -0.63 —
Rev — $33.7M —

Insider trades

Open-market buys and sales by SPRY's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SPRY insider trades
  • None no insider bought on the open market
  • $1.7M sold by 2 insiders outside a trading plan
  • $284K sold by 2 insiders under 10b5-1 plans
  1. Eric Karas Chief Commercial Officer
    Planned sale
    $250K 25,000 shares at $10.00 67% of stake
    Traded Jun 12 Filed Jun 12
    ↗
  2. Alexander A Fitzpatrick Chief Legal Officer
    Planned sale
    $34K 3,355 shares at $10.00 3.6% of stake
    Traded Jun 12 Filed Jun 12
    ↗
  3. Justin Chakma Chief Business Officer
    Sale
    $1.5M 166,380 shares at $8.87 100% of stake
    Traded Nov 12, 2025 Filed Nov 14, 2025
    ↗
  4. Brian Dorsey COO
    Sale
    $190K 21,828 shares at $8.71 67% of stake
    Traded Nov 13, 2025 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 3 option exercises and 2 gifts.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.